• Topotecan HCl: Bridging Mechanism and Strategy in Oncology R

  2026-07-27

  This thought-leadership article from APExBIO delves into the mechanistic underpinnings and translational strategies for deploying Topotecan HCl—a potent topoisomerase 1 inhibitor—in cancer research. We integrate the latest evidence on DNA damage responses, highlight competitive benchmarks, and provide actionable protocol guidance for researchers targeting lung and prostate tumor models. The discussion uniquely contextualizes Topotecan HCl’s role in the broader landscape of DNA-damage-driven pathology, referencing both oncology and neuroinflammatory findings to inform next-generation research.

• Cholecystokinin Octapeptide Ammonium: Reliable Solutions for

  2026-07-27

  This article provides scenario-driven guidance for biomedical researchers and lab technicians on leveraging Cholecystokinin octapeptide ammonium (SKU C8717) in cell viability, proliferation, and cytotoxicity assays. It addresses common workflow challenges—such as concentration selection, receptor specificity, and vendor reliability—while grounding recommendations in peer-reviewed literature and validated protocols. APExBIO’s C8717 is highlighted for its reproducibility and data-backed performance.

• Flavone Glucosides and Baicalin Methyl Ester from Scutellari

  2026-07-26

  The reference study identified and structurally characterized two novel flavone 2'-glucosides, along with several known phenolics including baicalin methyl ester, from Scutellaria baicalensis roots. These findings deepen our understanding of the plant’s flavonoid diversity and provide a rigorous foundation for subsequent mechanistic studies on intestinal barrier protection and inflammation modulation.

• MMP7 Drives EMT via E-cadherin/β-catenin in Biliary Atresia

  2026-07-25

  This study identifies matrix metalloproteinase 7 (MMP7) as a key driver of epithelial–mesenchymal transition (EMT) and liver fibrosis in biliary atresia via the E-cadherin/β-catenin pathway. The findings highlight MMP7 as a promising therapeutic target for mitigating fibrotic progression in this severe pediatric disease.

• hiPSC-Derived Intestinal Organoids Advance Pharmacokinetic S

  2026-07-24

  This study introduces a direct 3D cluster protocol to generate human pluripotent stem cell-derived intestinal organoids (hiPSC-IOs) for improved pharmacokinetic research. The model advances reproducibility and physiological relevance in drug absorption and metabolism studies, addressing longstanding limitations of traditional animal and Caco-2 cell systems.

• CCT007093: Illuminating PPM1D Inhibition in Cancer and AKI R

  2026-07-24

  Explore how CCT007093, a potent PPM1D inhibitor, enables advanced dissection of P38 MAPK signaling in cancer and kidney injury models. This article offers a unique perspective on integrating biochemical specificity with translational assay design.

• Moxidectin: Macrocyclic Lactone Anthelmintic in Antifungal P

  2026-07-23

  Moxidectin, a macrocyclic lactone anthelmintic, is now redefining antifungal research by synergizing with polyenes to suppress Candida albicans more effectively. This article details actionable workflows, protocol refinements, and troubleshooting strategies to maximize reproducibility and translational impact using high-purity Moxidectin from APExBIO.

• Lopinavir (ABT-378): Advancing HIV and Cross-Pathogen Resear

  2026-07-23

  This thought-leadership article explores Lopinavir (ABT-378) as a paradigm-shifting tool for translational HIV research, highlighting its mechanistic strengths, validation across evolving resistance landscapes, and emerging significance in cross-pathogen antiviral studies. Drawing on landmark evidence, including its role in inhibiting MERS-CoV, the piece offers protocol guidance and strategic foresight for researchers seeking robust, future-ready antiviral solutions.

• Redefining mRNA Delivery: Mechanistic Insight Meets Translat

  2026-07-22

  This article explores the mechanistic advances and translational strategies enabled by EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP), focusing on its dual-reporter capabilities, immune evasion, and high-fidelity quantitation. It connects biological rationale, experimental rigour, and actionable guidance—bridging competitive benchmarking and clinical relevance for next-generation mRNA research.

• AZD8055: Technical Use Guidance for mTOR Inhibition Studies

  2026-07-22

  AZD8055 is a highly selective ATP-competitive mTOR inhibitor suitable for dissecting both mTORC1 and mTORC2 signaling in preclinical cancer and metabolic research. It is not intended for studies focusing on clinical efficacy endpoints due to limited translation in late-phase trials. Proper workflow execution and solubilization practices are essential to achieve reproducible experimental results.

• Ivermectin in Anti-Parasitic Research: Mechanisms, Limitatio

  2026-07-21

  Explore Ivermectin’s role as a broad-spectrum anti-parasitic in research, with a nuanced analysis of its mechanism, assay optimization, and translational relevance to immune modulation. This article uncovers scientific insights and protocol strategies not covered in conventional guides.

• Discovery of Selective PDK4 Inhibitors for Metabolic Disease

  2026-07-21

  This article analyzes the innovation and implications of novel pyruvate dehydrogenase kinase 4 (PDK4) inhibitors, with a focus on the allosteric compound 8c and its effects in metabolic, allergic, and cancer models. Insights into the structural design, selectivity, and translational relevance of PDK4 inhibition are discussed, providing a foundation for metabolic research and therapeutic exploration.

• Oligomycin A: Precision Tools for Mitochondrial Dysfunction

  2026-07-20

  Explore how Oligomycin A, a mitochondrial ATP synthase inhibitor, advances mitochondrial bioenergetics research and apoptosis pathway studies. This article uniquely connects sodium-driven energy failure insights to practical assay design, setting it apart from prior coverage.

• Streamlining Bitespiramycin Biosynthesis: Targeted Gene Dele

  2026-07-20

  This study demonstrates the rational engineering of Streptomyces spiramyceticus to produce a single, major acetoxy-substituted macrolide antibiotic component—400-isovalerylspiramycin I—by in-frame partial deletion of the 3-O-acyltransferase gene. The approach simplifies bitespiramycin composition, facilitating quality control and downstream applications for antibacterial agent research.

• G-Quadruplexes Regulate TDP-43 Aggregation and Toxicity in A

  2026-07-19

  Oldani et al. reveal that RNA G-quadruplexes directly modulate TDP-43 protein condensation, intracellular distribution, and cytotoxicity in vitro and across cell models. Their work establishes G-quadruplex targeting as a promising mechanistic approach for mitigating TDP-43-driven neurodegeneration, with implications for ALS and related diseases.

467 records 11/32 page Previous Next First page 上5页 1112131415 下5页 Last page